Rocket Pharmaceuticals to Host Conference Call to Reveal First AAV Gene Therapy Program
Nov 25, 2018
|
Conference Call Scheduled for Monday, November 26, 2018, at 8:30 a.m.
ET
NEW YORK--(BUSINESS WIRE)--Nov. 25, 2018--
Rocket
Pharmaceuticals, Inc. (Nasdaq: RCKT) (“Rocket”), a leading
U.S.-based multi-platform gene therapy company, today announces that
management will host a conference call on Monday, November 26th ,
2018, at 8:30 a.m. ET to reveal their first adeno-associated viral
vector (AAV) gene therapy program.
To participate in the conference call, please dial (866) 679-4266 in the
U.S. or (409) 217-8318 outside of the U.S. five minutes prior to the
start of the call and provide the Conference ID of 5673299 or access the
listen-only webcast by visiting the Company’s website at www.rocketpharma.com.
An archive of the webcast will be available on the Company’s website for
thirty days.
About Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”) is an emerging,
clinical-stage biotechnology company focused on developing
first-in-class gene therapy treatment options for rare, devastating
diseases. Rocket’s multi-platform development approach applies the
well-established lentiviral vector (LVV) and adeno-associated viral
vector (AAV) gene therapy platforms. Rocket's lead clinical program is a
LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a
difficult to treat genetic disease that leads to bone marrow failure and
potentially cancer. Preclinical studies of additional bone
marrow-derived disorders are ongoing and target Pyruvate Kinase
Deficiency (PKD), Leukocyte Adhesion Deficiency-I (LAD-I) and Infantile
Malignant Osteopetrosis (IMO). Rocket is also developing an AAV-based
gene therapy program for an undisclosed rare pediatric disease. For more
information about Rocket, please visit www.rocketpharma.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181125005027/en/
Source: Rocket Pharmaceuticals, Inc.
Claudine Prowse, Ph.D.
SVP, Corporate Strategy and IRO
Rocket
Pharma, Inc.
The Empire State Building, Suite 7530
New York,
NY 10118
cp@rocketpharma.com
www.rocketpharma.com
investors@rocketpharma.com